abstract |
The present invention relates to the use of 2-chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for the treatment or amelioration of an autoimmune neuromuscular disorder for example, autoimmune myasthenia gravis (MG) neuromuscular disorder. |